Nature Medicine, volume 17, issue 4, pages 500-503
Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy
Collisson Eric A.
1, 2
,
Sadanandam Anguraj
1, 3
,
Olson Peter
4, 5
,
Gibb William J
1, 5
,
Truitt Morgan
4
,
Gu Shenda
1
,
Cooc Janine
6
,
Weinkle Jennifer
1
,
Kim Grace E.
7
,
Jakkula Lakshmi
1
,
Feiler Heidi S.
1
,
Ko Andrew H.
2
,
Olshen Adam B.
8
,
Danenberg Kathleen L
6
,
Tempero Margaret A.
2
,
Spellman Paul T.
1
,
Hanahan Douglas
3, 4
,
Gray Joe W.
1, 9
2
Division of Hematology and Oncology, University of California–San Francisco (UCSF), San Francisco, USA
|
4
Diabetes Center and Department of Biochemistry and Biophysics, UCSF, San Francisco, USA
|
5
Present addresses: Pfizer, La Jolla, California, USA (P.O.) and Genomic Health, Redwood City, California, USA (W.J.G.).,
|
6
Response Genetics, Los Angeles, USA
|
7
Department of Pathology, UCSF, San Francisco, USA
|
8
Department of Epidemiology and Biostatistics and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, USA
|
9
Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA
|
Publication type: Journal Article
Publication date: 2011-04-03
Journal:
Nature Medicine
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor: 82.9
ISSN: 10788956, 1546170X
DOI:
10.1038/nm.2344
PubMed ID:
21460848
General Biochemistry, Genetics and Molecular Biology
General Medicine
Abstract
This report describes the identification of three molecularly distinct subtypes of pancreatic ductal adenocarninoma (PDA). The classical, quasimesenchymal and exocrine subtypes can further stratify tumors with the same genetic alterations, and could be useful to improve prognosis and predict treatment response. Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis1. Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do occasionally respond. Studies in other solid tumors have shown that heterogeneity in response is determined, in part, by molecular differences between tumors. Furthermore, treatment outcomes are improved by targeting drugs to tumor subtypes in which they are selectively effective, with breast2 and lung3 cancers providing recent examples. Identification of PDA molecular subtypes has been frustrated by a paucity of tumor specimens available for study. We have overcome this problem by combined analysis of transcriptional profiles of primary PDA samples from several studies, along with human and mouse PDA cell lines. We define three PDA subtypes: classical, quasimesenchymal and exocrine-like, and we present evidence for clinical outcome and therapeutic response differences between them. We further define gene signatures for these subtypes that may have utility in stratifying patients for treatment and present preclinical model systems that may be used to identify new subtype specific therapies.
Citations by journals
|
10
20
30
40
50
60
70
80
90
|
|
|
Cancers
|
Cancers
86 publications, 6.35%
|
|
Clinical Cancer Research
|
Clinical Cancer Research
46 publications, 3.39%
|
|
Gut
|
Gut
29 publications, 2.14%
|
|
Scientific Reports
|
Scientific Reports
28 publications, 2.07%
|
|
Gastroenterology
|
Gastroenterology
27 publications, 1.99%
|
|
Oncotarget
|
Oncotarget
26 publications, 1.92%
|
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
22 publications, 1.62%
|
|
Frontiers in Oncology
|
Frontiers in Oncology
19 publications, 1.4%
|
|
PLoS ONE
|
PLoS ONE
19 publications, 1.4%
|
|
Cancer Discovery
|
Cancer Discovery
19 publications, 1.4%
|
|
Nature Communications
|
Nature Communications
18 publications, 1.33%
|
|
Pancreatology
|
Pancreatology
15 publications, 1.11%
|
|
Cancer Research
|
Cancer Research
15 publications, 1.11%
|
|
Frontiers in Cell and Developmental Biology
|
Frontiers in Cell and Developmental Biology
14 publications, 1.03%
|
|
Cell Reports
|
Cell Reports
13 publications, 0.96%
|
|
Cancer Cell
|
Cancer Cell
13 publications, 0.96%
|
|
BMC Cancer
|
BMC Cancer
12 publications, 0.89%
|
|
Frontiers in Immunology
|
Frontiers in Immunology
11 publications, 0.81%
|
|
Cells
|
Cells
10 publications, 0.74%
|
|
Pancreas
|
Pancreas
10 publications, 0.74%
|
|
Oncogene
|
Oncogene
10 publications, 0.74%
|
|
Translational Oncology
|
Translational Oncology, 10, 0.74%
Translational Oncology
10 publications, 0.74%
|
|
World Journal of Gastroenterology
|
World Journal of Gastroenterology
9 publications, 0.66%
|
|
EBioMedicine
|
EBioMedicine
9 publications, 0.66%
|
|
Cell
|
Cell
9 publications, 0.66%
|
|
Translational Cancer Research
|
Translational Cancer Research
9 publications, 0.66%
|
|
Cancer Letters
|
Cancer Letters
8 publications, 0.59%
|
|
Cancer Medicine
|
Cancer Medicine
8 publications, 0.59%
|
|
Molecular Oncology
|
Molecular Oncology
8 publications, 0.59%
|
|
10
20
30
40
50
60
70
80
90
|
Citations by publishers
|
50
100
150
200
250
|
|
|
Springer Nature
|
Springer Nature
246 publications, 18.15%
|
|
Elsevier
|
Elsevier
224 publications, 16.53%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
141 publications, 10.41%
|
|
American Association for Cancer Research (AACR)
|
American Association for Cancer Research (AACR)
97 publications, 7.16%
|
|
Wiley
|
Wiley
63 publications, 4.65%
|
|
Frontiers Media S.A.
|
Frontiers Media S.A.
55 publications, 4.06%
|
|
BMJ
|
BMJ
32 publications, 2.36%
|
|
Impact Journals
|
Impact Journals
28 publications, 2.07%
|
|
Wolters Kluwer Health
|
Wolters Kluwer Health
25 publications, 1.85%
|
|
Taylor & Francis
|
Taylor & Francis
25 publications, 1.85%
|
|
AME Publishing Company
|
AME Publishing Company
25 publications, 1.85%
|
|
Public Library of Science (PLoS)
|
Public Library of Science (PLoS)
22 publications, 1.62%
|
|
Oxford University Press
|
Oxford University Press
17 publications, 1.25%
|
|
American Society of Clinical Oncology (ASCO)
|
American Society of Clinical Oncology (ASCO)
13 publications, 0.96%
|
|
American Society for Clinical Investigation
|
American Society for Clinical Investigation
10 publications, 0.74%
|
|
Baishideng Publishing Group
|
Baishideng Publishing Group
10 publications, 0.74%
|
|
Neoplasia Press
|
Neoplasia Press, 10, 0.74%
Neoplasia Press
10 publications, 0.74%
|
|
EMBO press
|
EMBO press
8 publications, 0.59%
|
|
Future Medicine
|
Future Medicine
7 publications, 0.52%
|
|
SAGE
|
SAGE
7 publications, 0.52%
|
|
Proceedings of the National Academy of Sciences (PNAS)
|
Proceedings of the National Academy of Sciences (PNAS)
7 publications, 0.52%
|
|
S. Karger AG
|
S. Karger AG
6 publications, 0.44%
|
|
Spandidos Publications
|
Spandidos Publications
6 publications, 0.44%
|
|
eLife Sciences Publications
|
eLife Sciences Publications
5 publications, 0.37%
|
|
Hindawi Limited
|
Hindawi Limited
5 publications, 0.37%
|
|
Cold Spring Harbor Laboratory
|
Cold Spring Harbor Laboratory
5 publications, 0.37%
|
|
Pleiades Publishing
|
Pleiades Publishing
4 publications, 0.3%
|
|
American Society for Biochemistry and Molecular Biology
|
American Society for Biochemistry and Molecular Biology
4 publications, 0.3%
|
|
American Association for the Advancement of Science (AAAS)
|
American Association for the Advancement of Science (AAAS)
4 publications, 0.3%
|
|
50
100
150
200
250
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2011,2012,2013,2014,2015,2016,2017,2018,2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0,0,0,0,0,0,0,0,0],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["","","","","","","","","","","","","",""],"datasets":[{"label":"Citations number","data":[9,37,41,34,62,73,100,108,133,186,198,173,164,37],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["0.66","2.73","3.03","2.51","4.58","5.39","7.38","7.97","9.82","13.73","14.61","12.77","12.1","2.73"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Cancers","Clinical Cancer Research","Gut","Scientific Reports","Gastroenterology","Oncotarget","International Journal of Molecular Sciences","Frontiers in Oncology","PLoS ONE","Cancer Discovery","Nature Communications","Pancreatology","Cancer Research","Frontiers in Cell and Developmental Biology","Cell Reports","Cancer Cell","BMC Cancer","Frontiers in Immunology","Cells","Pancreas","Oncogene","Translational Oncology","World Journal of Gastroenterology","EBioMedicine","Cell","Translational Cancer Research","Cancer Letters","Cancer Medicine","Molecular Oncology"],"ids":[22471,6723,11195,13767,23571,8484,14627,10990,24963,8386,3231,21529,11199,12128,9130,23070,6868,1699,25293,8074,20423,15165,19469,23878,16552,22488,1654,20286,19249],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp","\/storage\/images\/resized\/hysFKdIDQMKHPbF1uLxJ3M6dQA4gPVuC6ZeA7m5a_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/HY0CXgRt044tzIAB16PDvDzdHeKHGtSvlMH0yWf6_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","","\/storage\/images\/resized\/bKOjgSt9mSGUD9fzKZyqcKSIgDCDSMd1ZWjJOZzx_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/PYBAYQjpFdxPQPRGY3kU5Xzbu0W7K7umVNk0TY9i_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp"],"datasets":[{"label":"","data":[86,46,29,28,27,26,22,19,19,19,18,15,15,14,13,13,12,11,10,10,10,10,9,9,9,9,8,8,8],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[6.35,3.39,2.14,2.07,1.99,1.92,1.62,1.4,1.4,1.4,1.33,1.11,1.11,1.03,0.96,0.96,0.89,0.81,0.74,0.74,0.74,0.74,0.66,0.66,0.66,0.66,0.59,0.59,0.59],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Springer Nature","Elsevier","Multidisciplinary Digital Publishing Institute (MDPI)","American Association for Cancer Research (AACR)","Wiley","Frontiers Media S.A.","BMJ","Impact Journals","Wolters Kluwer Health","Taylor & Francis","AME Publishing Company","Public Library of Science (PLoS)","Oxford University Press","American Society of Clinical Oncology (ASCO)","American Society for Clinical Investigation","Baishideng Publishing Group","Neoplasia Press","EMBO press","Future Medicine","SAGE","Proceedings of the National Academy of Sciences (PNAS)","S. Karger AG","Spandidos Publications","eLife Sciences Publications","Hindawi Limited","Cold Spring Harbor Laboratory","Pleiades Publishing","American Society for Biochemistry and Molecular Biology","American Association for the Advancement of Science (AAAS)"],"ids":[8,17,202,2286,11,208,6954,342,32,18,1566,344,19,73,564,7719,4513,9415,6949,31,162,6998,1097,6627,6921,6909,101,2090,189],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/hysFKdIDQMKHPbF1uLxJ3M6dQA4gPVuC6ZeA7m5a_medium.webp","\/storage\/images\/resized\/HY0CXgRt044tzIAB16PDvDzdHeKHGtSvlMH0yWf6_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/PYBAYQjpFdxPQPRGY3kU5Xzbu0W7K7umVNk0TY9i_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/0WrbuCPHoMon4eqSaqLoeO1owjv6jeDiHASSYzbS_medium.webp","\/storage\/images\/resized\/aFa86lAy63Pq5tYKiOsH017UsgJA6uk6ed66C0Ns_medium.webp","\/storage\/images\/resized\/bKOjgSt9mSGUD9fzKZyqcKSIgDCDSMd1ZWjJOZzx_medium.webp","","\/storage\/images\/resized\/1UiI5HycPsvulDeXOySNp0OuaMMmIKfPnsdKPyH0_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/mxFdPe9qujsfvfYfcN0QOclAiYORFb0xrRlwV8gs_medium.webp","\/storage\/images\/resized\/dzjTgJDYMoGfxybjlxLdd3z4gHYG42WZR0UxSYzy_medium.webp","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/eIZgkq1MRZyJ3hBkdupnUUv7wgB6zCl9D99SlPN5_medium.webp","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/hg4jJjT8wVGtHstBCc0zk465Mg9pLx3G4odCDOqE_medium.webp","\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/OuA6WPZekwEiUM99mP2pSqj4yHPxHezM6xgLhAjO_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp"],"datasets":[{"label":"","data":[246,224,141,97,63,55,32,28,25,25,25,22,17,13,10,10,10,8,7,7,7,6,6,5,5,5,4,4,4],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[18.15,16.53,10.41,7.16,4.65,4.06,2.36,2.07,1.85,1.85,1.85,1.62,1.25,0.96,0.74,0.74,0.74,0.59,0.52,0.52,0.52,0.44,0.44,0.37,0.37,0.37,0.3,0.3,0.3],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Collisson E. A. et al. Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy // Nature Medicine. 2011. Vol. 17. No. 4. pp. 500-503.
GOST all authors (up to 50)
Copy
Collisson E. A., Sadanandam A., Olson P., Gibb W. J., Truitt M., Gu S., Cooc J., Weinkle J., Kim G. E., Jakkula L., Feiler H. S., Ko A. H., Olshen A. B., Danenberg K. L., Tempero M. A., Spellman P. T., Hanahan D., Gray J. W. Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy // Nature Medicine. 2011. Vol. 17. No. 4. pp. 500-503.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/nm.2344
UR - https://doi.org/10.1038%2Fnm.2344
TI - Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy
T2 - Nature Medicine
AU - Collisson, Eric A.
AU - Sadanandam, Anguraj
AU - Olson, Peter
AU - Gibb, William J
AU - Truitt, Morgan
AU - Gu, Shenda
AU - Cooc, Janine
AU - Weinkle, Jennifer
AU - Kim, Grace E.
AU - Jakkula, Lakshmi
AU - Feiler, Heidi S.
AU - Ko, Andrew H.
AU - Olshen, Adam B.
AU - Danenberg, Kathleen L
AU - Tempero, Margaret A.
AU - Spellman, Paul T.
AU - Hanahan, Douglas
AU - Gray, Joe W.
PY - 2011
DA - 2011/04/03 00:00:00
PB - Springer Nature
SP - 500-503
IS - 4
VL - 17
PMID - 21460848
SN - 1078-8956
SN - 1546-170X
ER -
Cite this
BibTex
Copy
@article{2011_Collisson,
author = {Eric A. Collisson and Anguraj Sadanandam and Peter Olson and William J Gibb and Morgan Truitt and Shenda Gu and Janine Cooc and Jennifer Weinkle and Grace E. Kim and Lakshmi Jakkula and Heidi S. Feiler and Andrew H. Ko and Adam B. Olshen and Kathleen L Danenberg and Margaret A. Tempero and Paul T. Spellman and Douglas Hanahan and Joe W. Gray},
title = {Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy},
journal = {Nature Medicine},
year = {2011},
volume = {17},
publisher = {Springer Nature},
month = {apr},
url = {https://doi.org/10.1038%2Fnm.2344},
number = {4},
pages = {500--503},
doi = {10.1038/nm.2344}
}
Cite this
MLA
Copy
Collisson, Eric A., et al. “Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy.” Nature Medicine, vol. 17, no. 4, Apr. 2011, pp. 500-503. https://doi.org/10.1038%2Fnm.2344.